Leaving the W.H.O. Could Hurt Americans on a Range of Health Matters

Published On Jan 29, 2025, 5:01 AM

President Trump's decision to withdraw the U.S. from the World Health Organization (W.H.O.) could lead to significant negative outcomes for both global health initiatives and the U.S. public. Experts warn that this withdrawal would deprive the U.S. of critical health data, weaken its influence in global health matters, and empower rival nations like Russia and China. Additionally, the decision may adversely affect U.S. pharmaceutical and health technology firms, given the W.H.O.'s role in disease surveillance and health policy formulation.

Stock Forecasts

PFE

Negative

The announcement of withdrawal is likely to have a negative impact on the public health sector and related industries that depend on global health initiatives and data. Companies in the healthcare and biotech fields, like Pfizer and Moderna, may see a decline in stock prices due to the uncertainty and potential loss of business abroad.

XLV

Negative

Healthcare ETFs may also experience downward pressure as investors react to the news affecting the larger health landscape. A diversified health-focused ETF like the Health Care Select Sector SPDR Fund might see short-term drops as concerns about the U.S.'s loss of influence materialize.

Related News

A group of 15 states have reached a tentative new deal that would require them to set aside hundreds of millions of dollars from the settlement in a legal-defense fund for the family.

An aging U.S. population and lower risk of replacement by A.I. has contributed to strong demand for health care workers.

But the report, on the experiences of 13 patients, found that the drug had no benefit for some people and that some who benefited said the improvement didn’t last.